{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-152652","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.868595+00:00","generated_at":"2026-05-18T14:35:23.308849+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Dyne Therapeutics enters $275M loan agreement with Hercules Capital; $100M funded immediately","bullets":["Initial tranche of $100M funded on June 27, 2025; additional tranches up to $175M available upon milestones and lender discretion.","Interest rate of WSJ Prime + 2.45% (floor 7.50%); maturity July 1, 2030; interest-only until July 1, 2028, extendable.","First-priority security interest on substantially all assets including IP; covenants include minimum cash and minimum net product revenue post-approval of DYNE-101 or DYNE-251.","Prepayment penalty ranges from 0.75% to 2.0% of prepaid amount; end-of-term charge of 5.5%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-152652","json":"https://secwatch.observer/filing/0001193125-25-152652.json","markdown":"https://secwatch.observer/filing/0001193125-25-152652.md","text":"https://secwatch.observer/filing/0001193125-25-152652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525152652/0001193125-25-152652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525152652/d80696d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T14:35:23.308849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70c39cc16613dc804b7c3952fc2c3ffb2853f455","claim":"Dyne Therapeutics, Inc. incurred credit facility of up to $275.0 million with Hercules Capital, Inc. at Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45% maturing July 1, 2030.","evidence_excerpt":"The Loan Agreement provides for term loans in an aggregate principal amount of up to $275.0 million under multiple tranches","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525152652/0001193125-25-152652-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"up to $275.0 million"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Rate","value":"Wall Street Journal prime rate, subject to a floor of 7.50%, plus 2.45%"},{"label":"Maturity","value":"July 1, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}